Thursday 11 June 2015, Amsterdam
The report, now available on ASDReports, recognizes the following companies as the key players in the global benign prostatic hyperplasia market: Endo Health Solutions, Karl Storz, Lumenis, Olympus and Urologix
Other Prominent Vendors in the market are: Boston Scientific, Coloplast, Lisa Laser, Medi-tate, Medifocus, Neotract, ProArc Medical and UroTech
Commenting on the report, an analyst said: “The introduction of anesthesia and improved, simpler, and safer procedures have led to a paradigm shift from inpatient surgeries to same-day outpatient procedures. Numerous ambulatory surgical centers have also contributed to the increase in outpatient procedures. Cost effectiveness and convenience are the two major advantages of these procedures. TURP and TUMT are procedures that can be performed on an outpatient basis. Apart from these factors, countries such as the US provide reimbursements for such outpatient procedures, which will result in their increased adoption.”
According to the report, benign prostatic hyperplasia is associated with advancing age and obstructs the urinary system in males. Urinary problems, depression, and decreased quality of life are symptoms of benign prostatic hyperplasia. The Centers for Disease Control and Prevention reported that 37-million Americans had this condition in 2014.
Further, the report states that the availability of alternative methods restricts people from opting for surgical treatment options.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.